Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Posaconazole tablet
DRUG
2 trials
Sponsors
Merck Sharp & Dohme LLC
, Institute of Hematology & Blood Diseases Hospital, China
Conditions
Graft Versus Host Disease
Hematopoietic Stem Cell Transplantation
Invasive Aspergillosis
Invasive Fungal Disease
Phase 2
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Completed
NCT04218851
Merck Sharp & Dohme LLC
Invasive Aspergillosis
Start: 2020-07-02
End: 2023-12-18
Updated: 2025-01-14
Unknown Phase
Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
Enrolling by invitation
NCT06698211
Institute of Hematology & Blood Diseases Hospital, China
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Invasive Fungal Disease
Start: 2023-08-01
End: 2025-01-01
Target: 40
Updated: 2024-11-20
Related Papers
Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease.
2026-01-27